 |
|
|
| |
Phase 3 Randomized, Controlled DISCOVER Study of Daily F/TAF or F/TDF for HIV Pre-exposure Prophylaxis: Week 96 Results
|
| |
| |
17th European AIDS Conference (EACS), 6-9 November 2019, Basel, Switzerland
Reported by Jules Levin
Peter Ruane,1 Amanda Clarke,2 Frank A. Post,3 Gabriel Schembri,4 Heiko Jessen,5 Benoit Trottier,6 Colm Bergin,7 Jean-Michel Molina,8 Pamela Wong,9 Ramin Ebrahimi,9 Diana Brainard,9 Anu Osinusi,9 Moupali Das,9 Scott McCallister9
1Ruane Medical & Liver Health Institute, Los Angeles, California, USA; 2Brighton and Sussex University Hospitals, Brighton, UK; 3King's College Hospital, London, UK; 4Central Manchester University Hospitals, Manchester, UK; 5Praxis Jessen2 + Kollegen: Academic Teaching Clinic of Charite Universitatsmedizin Berlin, Germany; 6Clinique Medicale Urbaine du Quartier Latin, Montreal, Quebec, Canada; 7St James's Hospital, Dublin, Ireland; 8Universite Paris Diderot, Paris, France; 9Gilead Sciences, Inc., Foster City, California
References: 1. Descovy [package insert]. Foster City, CA: Gilead Sciences, Inc., 10/2019; 2. Hare CB, et al. CROI 2019, abstr 104; 3. Glidden DV, et al. Clin Infect Dis 2018;67:411-9.
|
| |
|
|
|
|
|
